Biohaven Pharmaceutical Holding Co Ltd
Biohaven Pharmaceutical — Technical Presentation (March 2018)
19 slides from Biohaven Pharmaceutical's technical presentation, Mar 26, 2018
Slide 1: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking statements, including: statements about our plans to develop rimegepant, including the timing for regulatory submissions, and the safety and efficacy of rimegepant. These statements involve substantial known and unknown risks, unce
Slide 2: Rimegepant 75 mg Phase 3 Top Line Summary from Study 301 and Study 302: Acute Treatment of Migraine
Rimegepant 75 mg Phase 3 Top Line Summary from Study 301 and Study 302: Acute Treatment of Migraine ©2018 Biohaven
Slide 3: Overview: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials
Overview: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant Rimegepant met both registrational co-primary endpoints (pain freedom and freedom from most bothersome symptom at 2 hours) in two pivotal Phase 3 trials Results statistically signific
Slide 4: Design for Pivotal Phase 3 Trials of Rimegepant: Studies 301 and 302
Design for Pivotal Phase 3 Trials of Rimegepant: Studies 301 and 302 Screening Randomization Phase End of Study Visit Up to 45 days 3-28 days Within 7 days of Dosing (+2 days) Rimegepant 75 mg Placebo 1:1 Randomization End of Study Visit Study 301 and Study 302 had identical study designs: 301: 1162
Slide 5: Descriptive Summary of Pooled Study Demographics
Descriptive Summary of Pooled Study Demographics1: Trials Representative of Typical Migraine Patient Population Patient Demographics and Migraine History Female > Male (~85% F; 15% M) Average age = ~40 years old Diverse patient population across the U.S. Mean number of historical moderate to severe
Slide 6: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials
Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant 2 hour Endpoint Rimegepant n=537 Placebo n=535 p-value Pain Freedom 19.6% 12.0% < 0.001 Freedom from MBS1 37.6% 25.2% < 0.0001 Study 302 2 hour Endpoint Rimegepant n=543 Placebo n=541 p-value P
Slide 7: Pain Freedom: Early Separation and Continued Improvement (Study 302)
Pain Freedom: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 302) Kaplan-Meier Curve of Time to Pain Freedom up to 8 Hours Post Single Dose Data are Kaplan-Meier estimates of pain freedom; subjects were censored (not included) who took rescue medica
Slide 8: Pain Freedom: Increasing Benefit Over Time (Study 302)
Pain Freedom: Increasing Benefit Over Time Single Dose of Rimegepant, No Rescue Meds (Study 302) ©2018 Biohaven Data are Kaplan-Meier estimates of pain freedom; subjects were censored (not included) who took rescue medication or were lost to follow-up during the specified interval % of Patients Pain
Slide 9: Pain Relief: Early Separation and Continued Improvement (Study 302)
Pain Relief: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 302) Kaplan-Meier Curve of Time to Pain Relief up to 8 Hours Post Single Dose Data are Kaplan-Meier estimates of pain relief; subjects were censored (not included) who took rescue medicatio
Slide 10: Pooled Liver Function Test (LFT) Profile: Rimegepant Similar to Placebo
Pooled Liver Function Test (LFT) Profile: Rimegepant was Similar to Placebo in Both Studies ALT or AST Rimegepant n=1089 Placebo n=1092 > ULN1 24 (2.2%) 32 (2.9%) > 3x ULN 1 (0.1%) 1 (0.1%) > 5x ULN 0 0 > 10x ULN 0 0 > 20x ULN 0 0 *No bilirubin elevations >2x ULN across both Studies 301 and 302 1ULN
Slide 11: Rimegepant was Well Tolerated: No Single Adverse Event Occurring >2%
Rimegepant was Well Tolerated: No Single Adverse Event Occurring > 2% Pooled Adverse Event (AE) Safety Data From Study 301 and Study 302 Percent (number) of Patients Reporting an Adverse Event within 48 Hours Post-Dose > 1% Incidence Adverse Event Placebo n=1092 Rimegepant n=1089 > 1 On-Study AE* 12
Slide 12: Summary: Successful Achievement of Both Co-Primary Regulatory Endpoints
Summary: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant Rimegepant met both registrational co-primary endpoints (pain freedom and freedom from most bothersome symptom at 2 hours) in two pivotal Phase 3 trials Results are statistically signi
Slide 13: Summary: Successful Achievement of Both Co-Primary Regulatory Endpoints
mmary: Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant * Rimegepant met both registrational co-primary endpoints (pain freedom and freedom from most bothersome symptom at 2 hours) in two pivotal Phase 3 trials * Results are statistically sig
Slide 14: Backup Slides
Backup Slides ©2018 Biohaven
Slide 15: Pain Freedom: Early Separation and Continued Improvement (Study 301)
Pain Freedom: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 301) Kaplan-Meier Curve of Time to Pain Freedom up to 8 Hours Post Single Dose Data are Kaplan-Meier estimates of pain freedom; subjects were censored (not included) who took rescue medica
Slide 16: Pain Freedom: Increasing Benefit Over Time (Study 301)
Pain Freedom: Increasing Benefit Over Time Single Dose of Rimegepant, No Rescue Meds (Study 301) ©2018 Biohaven Data are Kaplan-Meier estimates of pain freedom; subjects were censored (not included) who took rescue medication or were lost to follow-up during the specified interval Pain Freedom 2-8 H
Slide 17: Pain Relief: Early Separation and Continued Improvement (Study 301)
Pain Relief: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 301) Kaplan-Meier Curve of Time to Pain Relief up to 8 Hours Post Single Dose Data are Kaplan-Meier estimates of pain relief; subjects were censored (not included) who took rescue medicatio
Slide 18: Pain Relief: Early Separation and Continued Improvement (Study 301)
Pain Relief: Early Separation and Continued Improvement Without Additional Dosing or Rescue Medications (Study 301) Kaplan-Meier Curve of Time to Pain Relief up to 8 Hours Post Single Dose 1.0 TRnegenant eS) Study 301 | 0.9 0.8 0.7 0.6 0.5 0.4 0.3 Probability of Pain Relief 0.2 0.1 Single Dose of Ri
Slide 19: BHVN
BHVN LISTED 12018 Biohaven
Biohaven Pharmaceutical Holding — Technical Presentation (March 2018) on 6ix